TY  - RPRT
TI  - The defined TLR3 agonist, Nexavant, exhibits anti-cancer efficacy and potentiates anti-PD-1 antibody therapy by enhancing immune cell infiltration.
AU  - Kim, D.
AU  - Lee, S.-H.
AU  - Choi, Y.-H.
AU  - Kang, S.-M.
AU  - Lee, M.-G. L.
AU  - Hong, S.-B.
AU  - Perouzel, E.
AU  - Debin, A.
PY  - 2023
DO  - 10.1101/2023.10.25.564097
UR  - https://www.biorxiv.org/content/10.1101/2023.10.25.564097v1
ID  - 10.1101/2023.10.25.564097
ER  -